The DOI matches its Crossref record.
Pseudolaric acid B induces mitotic arrest and apoptosis in both 5-fluorouracil-sensitive and -resistant colorectal cancer cells
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“5-fluorouracil (5-FU) is commonly used alone or in combination with other chemotherapeutic drugs to treat CRC (Wen et al., 2016).”
From The use of chitosan-coated flexible liposomes as a remarkable carrier to enhance the antitumor efficacy of 5-fluorouracil against colorectal cancer (2019) · cites this paper as Wen et al., 2016
Experimental — accuracy not yet measuredIn the citing paper
“Unfortunately, this magnitude and duration of administration may aggravate the risk of adverse effect such as cardiotoxicity, myelosuppression, neurotoxicity and gastrointestinal upset (Wen et al., 2016).”
From The use of chitosan-coated flexible liposomes as a remarkable carrier to enhance the antitumor efficacy of 5-fluorouracil against colorectal cancer (2019) · cites this paper as Wen et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 50
- Ferlay, 2015, Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, Int. J. Cancer, 136, 359, 10.1002/ijc.29210 · DOI · Paper page
- Colucci, 2005, Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale, J. Clin. Oncol., 23, 4866, 10.1200/JCO.2005.07.113 · DOI
- Heinemann, 2014, FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial, Lancet Oncol., 15, 1065, 10.1016/S1470-2045(14)70330-4 · DOI · Paper page
- Longley, 2006, Drug resistance, predictive markers and pharmacogenomics in colorectal cancer, Biochim. Biophys. Acta, 1766, 184
- Newman, 2016, Natural products as Sources of new drugs from 1981 to 2014, J. Nat. Prod., 79, 629, 10.1021/acs.jnatprod.5b01055 · DOI · Paper page
- Breinbauer, 2002, From protein domains to drug candidates-natural products as guiding principles in the design and synthesis of compound libraries, Angew. Chem. Int. Ed. Engl., 41, 2879, 10.1002/1521-3773(20020816)41:16<2878::AID-ANIE2878>3.0.CO;2-B · DOI
- Zhou, 1991, Some progress on the chemistry of natural bioactive terpenoids from Chinese medicinal plants, Mem. Inst. Oswaldo Cruz., 86, 219, 10.1590/S0074-02761991000600049 · DOI
- Li, 1995, Antifungal evaluation of pseudolaric acid B, a major constituent of Pseudolarix kaempferi, J. Nat. Prod., 58, 57, 10.1021/np50115a007 · DOI
- Wong, 2005, Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo, Clin. Cancer Res., 11, 6002, 10.1158/1078-0432.CCR-05-0209 · DOI
- Ma, 2010, Selective inhibition of human leukemia cell growth and induction of cell cycle arrest and apoptosis by pseudolaric acid B, J. Cancer Res. Clin. Oncol., 136, 1333, 10.1007/s00432-010-0784-0 · DOI
- Yu, 2015, Pseudolaric acid B circumvents multidrug resistance phenotype in human gastric cancer SGC7901/ADR cells by downregulating Cox-2 and P-gp expression, Cell Biochem. Biophys., 71, 119, 10.1007/s12013-014-0170-7 · DOI
- Qi, 2013, MTOR inactivation by ROS-JNK-p53 pathway plays an essential role in psedolaric acid B induced autophagy-dependent senescence in murine fibrosarcoma L929 cells, Eur. J. Pharmacol., 715, 76, 10.1016/j.ejphar.2013.05.051 · DOI
- Tan, 2004, Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect, Eur. J. Pharmacol., 499, 219, 10.1016/j.ejphar.2004.07.063 · DOI
- Li, 2015, Pseudolaric acid B inhibits T-cell mediated immune response in vivo via p38MAPK signal cascades and PPARgamma activation, Life Sci., 121, 88, 10.1016/j.lfs.2014.11.020 · DOI
- Gong, 2006, Involvement of JNK-initiated p53 accumulation and phosphorylation of p53 in pseudolaric acid B induced cell death, Exp. Mol. Med., 38, 428, 10.1038/emm.2006.50 · DOI
- Zhao, 2012, Pseudolaric acid B induces apoptosis via proteasome-mediated Bcl-2 degradation in hormone-refractory prostate cancer DU145 cells, Toxicol. In Vitro, 26, 595, 10.1016/j.tiv.2012.02.004 · DOI
- Qi, 2012, Pseudolaric acid B induces mitotic catastrophe followed by apoptotic cell death in murine fibrosarcoma L929 cells, Eur. J. Pharmacol., 683, 16, 10.1016/j.ejphar.2012.02.035 · DOI
- Hou, 2012, Pseudolaric acid B inhibits inducible cyclooxygenase-2 expression via downregulation of the NF-kappaB pathway in HT-29 cells, J. Cancer Res. Clin. Oncol., 138, 885, 10.1007/s00432-011-1120-z · DOI
- Wen, 2015, Gambogic acid inhibits growth, induces apoptosis, and overcomes drug resistance in human colorectal cancer cells, Int. J. Oncol., 47, 1663, 10.3892/ijo.2015.3166 · DOI
- Mashima, 2005, P53-defective tumors with a functional apoptosome-mediated pathway: A new therapeutic target, J. Natl. Cancer Inst, 97, 765, 10.1093/jnci/dji133 · DOI
- Longley, 2006, C-FLIP inhibits chemotherapy-induced colorectal cancer cell death, Oncogene, 25, 838, 10.1038/sj.onc.1209122 · DOI
- Crosio, 2002, Mitotic phosphorylation of histone H3: Spatio-temporal regulation by mammalian Aurora kinases, Mol. Cell. Biol., 22, 874, 10.1128/MCB.22.3.874-885.2002 · DOI
- Brito, 2006, Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint, Curr. Biol., 16, 1194, 10.1016/j.cub.2006.04.043 · DOI
- Hisatomi, 2012, The regulatory roles of apoptosis-inducing factor in the formation and regression processes of ocular neovascularization, Am. J. Pathol., 181, 53, 10.1016/j.ajpath.2012.03.022 · DOI
- Delbridge, 2016, Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies, Nat. Rev. Cancer, 16, 99, 10.1038/nrc.2015.17 · DOI · Paper page
- Dynek, 2013, Antagonists of IAP proteins as cancer therapeutics, Cancer Lett., 332, 206, 10.1016/j.canlet.2010.06.013 · DOI
- Gascoigne, 2009, How do anti-mitotic drugs kill cancer cells?, J. Cell Sci., 122, 2579, 10.1242/jcs.039719 · DOI · Paper page
- Jordan, 2004, Microtubules as a target for anticancer drugs, Nat. Rev. Cancer, 4, 253, 10.1038/nrc1317 · DOI · Paper page
- Lara-Gonzalez, 2012, The spindle assembly checkpoint, Curr. Biol., 22, R966, 10.1016/j.cub.2012.10.006 · DOI
- Chu, 2012, Cdk1/cyclin B plays a key role in mitotic arrest-induced apoptosis by phosphorylation of Mcl-1, promoting its degradation and freeing Bak from sequestration, Biochem. Pharmacol., 83, 199, 10.1016/j.bcp.2011.10.008 · DOI
- Chang, 2016, Randomized controlled trial of intraportal chemotherapy combined with adjuvant chemotherapy (mFOLFOX6) for stage II and III colon cancer, Ann. Surg., 263, 434, 10.1097/SLA.0000000000001374 · DOI
- Allegra, 2011, Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08, J. Clin. Oncol., 29, 11, 10.1200/JCO.2010.30.0855 · DOI
- Ciardiello, 2016, Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase 2 trial of FOLFOX plus cetuximab versus FOLFOX, Ann. Oncol., 27, 1055, 10.1093/annonc/mdw136 · DOI
- Li, 2013, Gambogic acid is a tissue-specific proteasome inhibitor in vitro and in vivo, Cell Rep., 3, 211, 10.1016/j.celrep.2012.11.023 · DOI
- Shi, 2014, Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation, Clin. Cancer Res., 20, 151, 10.1158/1078-0432.CCR-13-1063 · DOI
- Yu, 2016, Pseudolaric acid B activates autophagy in MCF-7 human breast cancer cells to prevent cell death, Oncol. Lett., 11, 1731, 10.3892/ol.2016.4103 · DOI
- Yu, 2015, Pseudolaric acid B inhibits proliferation in SW579 human thyroid squamous cell carcinoma, Mol. Med. Rep., 12, 7195, 10.3892/mmr.2015.4418 · DOI
- Yu, 2013, Pseudolaric acid B induced cell cycle arrest, autophagy and senescence in murine fibrosarcoma l929 cell, Int. J. Med. Sci., 10, 707, 10.7150/ijms.5726 · DOI
- Li, 2015, Pseudolaric acid B exerts antitumor activity via suppression of the Akt signaling pathway in HeLa cervical cancer cells, Mol. Med. Rep., 12, 2021, 10.3892/mmr.2015.3615 · DOI
- Khan, 2012, Pseudolaric Acid B induces caspase-dependent and caspase-independent apoptosis in u87 glioblastoma cells, Evid. Based Complement. Altern. Med., 2012, 957568, 10.1155/2012/957568 · DOI
- Wang, 2013, Pseudolaric acid B induces apoptosis in U937 human leukemia cells via caspase-9mediated activation of the mitochondrial death pathway, Mol. Med. Rep., 8, 787, 10.3892/mmr.2013.1571 · DOI
- Shi, 2008, Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5, Cancer Res., 68, 3269, 10.1158/0008-5472.CAN-07-6699 · DOI
- Gascoigne, 2008, Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs, Cancer Cell, 14, 111, 10.1016/j.ccr.2008.07.002 · DOI · Paper page
- Li, 2016, Loss of p53-mediated cell-cycle arrest, senescence and apoptosis promotes genomic instability and premature aging, Oncotarget, 7, 11838, 10.18632/oncotarget.7864 · DOI
- Sarkar, 2012, Interaction of pseudolaric acid B with the colchicine site of tubulin, Biochem. Pharmacol., 84, 444, 10.1016/j.bcp.2012.05.014 · DOI
- Choi, 2015, Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells, Cancer Lett., 357, 591, 10.1016/j.canlet.2014.12.023 · DOI
- Galluzzi, 2012, Molecular definitions of cell death subroutines: recommendations of the nomenclature committee on cell death 2012, Cell Death Differ., 19, 107, 10.1038/cdd.2011.96 · DOI · Paper page
- Lanz, 2013, Mitotic catastrophe triggered in human cancer cells by the viral protein apoptin, Cell Death Dis., 4, e487, 10.1038/cddis.2013.2 · DOI
- Holt, 2009, Global analysis of Cdk1 substrate phosphorylation sites provides insights into evolution, Science, 325, 1682, 10.1126/science.1172867 · DOI
- Terrano, 2010, Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis, Mol. Cell. Biol., 30, 640, 10.1128/MCB.00882-09 · DOI
Cited by
Sorted by citations
Alomrani, A., Badran, M., Harisa, G. I., ALshehry, M., Alhariri, M., Alshamsan, A., & Alkholief, M. (2019) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2019.02.008 · Cited by 143
Metadata
- Authors
- Wen, C., Chen, J., Zhang, D., Wang, H., Che, J., Qin, Q., He, L., Cai, Z., Lin, M., Lou, Q., Huang, L., Chen, D., Iwamoto, A., Ren, D., Wang, L., Lan, P., Wang, J., Liu, H., & Yang, X.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 383
- Issue
- 2
- Pages
- 295-308
- ISSN
- 0304-3835
- Cited by
- 35
- References
- 0
- Language
- en
- Funders
- Guangdong Innovative Research Team Program (2009010058)
- Guangdong Provincial Department of Science and Technology (2012B050500004, 2014B020212016)
- National Key Clinical Discipline
- National Natural Science Foundation of China (81301978)
- Overseas Excellent Professor Project, Ministry of Education, China
- Japan Ministry of Education, Culture, Sports, Science and Technology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pseudolaric acid B induces mitotic arrest and apoptosis in both 5-fluorouracil-sensitive and -resistant colorectal cancer cells. https://app.cochat.ai/papers/10.1016/j.canlet.2016.09.007
- The paper
- Wen, C., Chen, J., Zhang, D., Wang, H., Che, J., Qin, Q., He, L., Cai, Z., Lin, M., Lou, Q., Huang, L., Chen, D., Iwamoto, A., Ren, D., Wang, L., Lan, P., Wang, J., Liu, H., & Yang, X. (2016). Pseudolaric acid B induces mitotic arrest and apoptosis in both 5-fluorouracil-sensitive and -resistant colorectal cancer cells. Cancer Letters. https://doi.org/10.1016/j.canlet.2016.09.007